The $7 Billion Gamble: How Private Equity Turned Autism Therapy into a High-Stakes Corporate Industry

By Investigative Staff

In a stark revelation that has sent shockwaves through the disability rights community and federal oversight agencies, a comprehensive investigation by The 74 has uncovered a systemic crisis in American autism care. Over a six-year period, private equity firms have aggressively consolidated the Applied Behavior Analysis (ABA) industry, effectively turning a taxpayer-funded health service into a $7 billion profit engine.

While federal agents have made headlines with high-profile raids on autism centers—often framing the issue through the lens of immigrant fraud or "welfare cheating"—the deeper, more pervasive scandal lies in the opaque, profit-driven strategies of private equity. By exploiting lax regulatory environments and high Medicaid reimbursement rates, these firms have prioritized volume over quality, often at the expense of the very children they were meant to support.

The Convergence of Fraud and Corporate Greed

The intersection of public policy and private profit began in earnest following the Obama-era expansion of the Affordable Care Act, which mandated that Medicaid cover autism treatment. While the intent was to ensure access to care, the lack of robust oversight created a "wild west" environment.

In February, the U.S. Department of Government Efficiency released a massive, 275-million-record dataset of Medicaid billing, allowing for unprecedented transparency. The 74 analyzed this data, revealing that Medicaid claims for the six most common autism therapy billing codes exploded by 381% between 2019 and 2024, ballooning from $400 million to nearly $2 billion annually.

This financial influx did not necessarily correlate with improved patient outcomes. Instead, it catalyzed a wave of consolidation. Private equity firms, attracted by the steady, government-backed revenue streams of ABA therapy, began hoovering up independent clinics. These firms often operate by saddling acquired clinics with debt, demanding high-volume service delivery to pay off that debt, and extracting management fees—all while keeping the underlying investment managers insulated from direct liability for patient harm.

A Chronology of Institutional Capture

The rise of the current ABA-industrial complex was not an accident; it was a decades-long process of legislative lobbying and institutional alignment.

• 2005–2007: Driven by a grassroots movement led by parents like Lorri Unumb, states began passing "Ryan’s Laws," which mandated private insurance coverage for ABA therapy. These efforts, while well-intentioned, codified ABA as the "gold standard" in state statutes, often ignoring the lack of independent, peer-reviewed evidence for its long-term efficacy.
• 2014: The federal government formally recognized autism therapy under the ACA, opening the floodgates for billions in Medicaid funding.
• 2015–2024: Private equity firms began an aggressive acquisition spree, purchasing 574 service sites across the country.
• 2022–2025: Federal audits of state Medicaid spending in red and blue states alike began to reveal significant billing irregularities, including "copy-paste" documentation, billing for custodial care (like lunch or naps), and the abandonment of academic schooling in favor of full-time, center-based therapy.

Supporting Data: The Cost of Compliance

The financial discrepancy between the ABA industry and traditional special education is staggering. While the U.S. has spent roughly $6 billion over two decades under the Autism CARES Act to improve the quality of life for autistic individuals, the ABA industry has extracted $7 billion in Medicaid funds in just six years.

Independent researchers have found that this focus on "compliance" and "extinguishing" behaviors—the core tenets of modern ABA—is increasingly linked to poor mental health outcomes. A landmark study from the University of Wisconsin-Madison, Ohio State University, and the University of Texas at Austin found that individuals who underwent ABA before age 18 were 30% more likely to require mental health hospitalization as adults.

Furthermore, the industry’s reliance on "behavior technicians"—the lowest-paid, least-trained staff—to perform hours of repetitive drills has drawn intense criticism. In Colorado, state auditors found that in 100% of reviewed cases, there were improper or potentially inappropriate claims, with some facilities failing to provide any diagnostic justification for the intensive 40-hour-a-week regimens they were billing to the state.

Official Responses and Industry Defense

The response from the industry has been one of compartmentalization. Lorri Unumb, now CEO of the Council of Autism Service Providers, maintains that the majority of ABA providers operate ethically. "Bad actors exist in every healthcare profession," Unumb stated, emphasizing that "thousands of qualified, ethical ABA providers are at work every day."

Private equity firms, meanwhile, have sought to distance themselves from clinical failures. Blackstone, which owned the troubled Center for Autism and Related Disorders (CARD) before its 2023 bankruptcy, stated that it was "never involved in specific clinical treatment decisions." They blamed the firm’s collapse on a "perfect storm" of COVID-19 lockdowns and labor shortages.

However, critics argue that the structure of private equity—where the parent firm faces no liability for the medical malpractice of its subsidiaries—is a feature, not a bug. "If a company gets caught in fraud, it’s just the cost of doing business," says Rosemary Batt, professor emeritus at Cornell University. The financial shield provided by the "portfolio company" model allows investors to extract capital and exit before the long-term consequences of underfunded, high-volume care manifest.

Implications for the Future of Autism Care

The implications of this investigation are profound. As the second Trump administration tightens Medicaid spending, there is a legitimate fear that legitimate, necessary services will be cut alongside fraudulent ones, leaving the most vulnerable without support.

Disability advocates are particularly concerned that the focus on "cures" and "behavior modification"—promoted by figures like Robert F. Kennedy Jr.—is drowning out the need for neurodiversity-affirming supports, such as occupational therapy, speech therapy, and inclusive education.

The Colorado legislative battle of 2026 serves as a microcosm of this struggle. Despite desperate pleas from autistic adults and parents to include independent, neurodivergent voices on the newly formed state licensing board, the final legislation largely solidified the power of the ABA industry. The board remains dominated by behavior analysts, effectively allowing the industry to police itself.

As Jenny Thamer, a parent in Boulder, noted in her testimony: "Autistic adults often compare ABA to gay conversion therapy, because the goal is often to make autistics appear less autistic, rather than helping them live safely and comfortably as themselves."

The path forward remains fraught. Without federal legislation that mandates joint liability for investment firms in healthcare, and without a shift in focus from "extinguishing" behaviors to supporting human dignity, the $7 billion currently spent annually on ABA threatens to continue reinforcing a system that many autistic people view as a relic of a dark, eugenicist past.

For the families trapped in this cycle, the promise of a "normal life" has become a costly, often traumatic distraction from the real work of providing autistic children with the accommodations and respect they deserve to thrive in society as their authentic selves. The question remains whether lawmakers will finally look past the lobbying power of the ABA industry and the opaque financial structures of private equity to address the human cost of these policies.